Literature DB >> 3942846

Lymphocytapheresis--a feasible treatment for rheumatoid arthritis.

P Emery, G N Smith, G S Panayi.   

Abstract

A short three-treatment out-patient course of lymphocytapheresis (LA) was compared with a standard six-treatment regimen in a group of rheumatoid arthritis patients pre-selected for poor cell-mediated immunity, which has been shown to be associated with a good response to LA. Significant clinical improvements were seen with both treatments. There did not appear to be any clear difference between three and six treatments. A short course of LA may represent a possible treatment for selected rheumatoid arthritis patients.

Entities:  

Mesh:

Year:  1986        PMID: 3942846     DOI: 10.1093/rheumatology/25.1.40

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  7 in total

Review 1.  Immunotherapy of rheumatoid arthritis.

Authors:  R A Watts; J D Isaacs
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

Review 2.  Anti-CD4 monoclonal antibodies in rheumatoid arthritis.

Authors:  E H Choy; G H Kingsley; G S Panayi
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis.

Authors:  C Barbadillo; A G-Arroyo; C Salas; J Mulero; F Sánchez-Madrid; J L Andreu
Journal:  Springer Semin Immunopathol       Date:  1995

Review 4.  Clinical use of cyclosporin in rheumatoid arthritis.

Authors:  C Richardson; P Emery
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  Exploring the feasibility of selective depletion of T lymphocyte subsets by whole blood immunoadsorption cytapheresis.

Authors:  M Belak; C R Valeri; D G Wright
Journal:  Clin Exp Immunol       Date:  2007-10-09       Impact factor: 4.330

6.  Photodynamic therapy; a comparison with other immunomodulatory treatments of adjuvant-enhanced arthritis in MRL-lpr mice.

Authors:  L G Ratkay; R K Chowdhary; H C Neyndorff; J Tonzetich; J D Waterfield; J G Levy
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

Review 7.  Gastro-oesophageal reflux disease.

Authors:  Ronnie Fass; Guy E Boeckxstaens; Hashem El-Serag; Rachel Rosen; Daniel Sifrim; Michael F Vaezi
Journal:  Nat Rev Dis Primers       Date:  2021-07-29       Impact factor: 52.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.